Type 2 Diabetes

Stem cells from bone marrow are being investigated as possible treatments for diabetes. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Type 2 Diabetes

  • Autologous Bone Marrow Stem Cells Transplantation for Diabetes Mellitus Location: China
    Overview: This trial seeks to investigate whether the patient's own bone marrow stem cells injected directly into the pancreas can assist those with type 2 diabetes. The trial will compare whether those participants receiving the stem cells and conventional treatment, respond differently to those who only receive conventional treatment. The trial is being conducted at the 452 PLA Hospital in China's Sichuan Province and aims to recruit a total of 60 subjects. Participants will be accessed for changes in blood and urine glucose regulation and the trial is expected to run until December 2015.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes Location: US
    Overview: This large multicentre trial in 11 US states, and sponsored by Australian company Mesoblast, is assessing the safety and effectiveness of donated cells (termed MPC-mesenchymal progenitor cells) in patients suffering from type 2 diabetes. The trial expects to recruit 60 participants suffering from type 2 diabetes that is not being properly controlled by current medication. The patients will be divided into three groups and given either a placebo (no cells) or different doses of donated Mesenchymal Precursor Cells. The participants will be assessed for complications and for changes in the control of their diabetes.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Stem Cells (unspecified)
  • Clinical Trial Phase I/II Multicentric, Open, Randomized and Controlled for the Study of Stem Cells as Therapy Critical Ischemia in Low Limbs in Insulinized Type 2 Diabetic Patients Location: Spain
    Overview: This trial is investigating the effects of patient's own stem cells as therapy for critical ischemia in lower limbs in patients with type 2 diabetics. The trial is being conducted by the Fundación progreso y Salud in Seville and seeks to compare the effects of injecting different stem cells as therapy for critical ischemia in lower limbs in type 2 diabetic patients. Participants must have non-healing ulcers older than four weeks and no potential for conventional treatment (eg revascularisation). Participants will be randomly allocated into groups receiving randomised to receiving either their own bone marrow stem cells; mesenchymal stem cells from their fat, or their own selected bone marrow stem cells (CD 133+ stem cells). The cells will be delivered directly into the artery of the affected limb. Participants will be monitored for complications and assessed for changes in their clinical condition. The study commenced in July 2011 and expects to enrol 48 patients.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus Location: China
    Overview: This trial aims to evaluate the safety and effectiveness of using the patient's bone marrow stem cells in treating type 2 diabetes. The trial is being conducted by the Peking University Aerospace Centre Hospital in Beijing and expects to enrol 500 patients by May 2015. Participants will be divided into those that require conventional oral treatment for their diabetes and those that also require insulin. Within these categories, participants will be further divided into those that only receive the standard treatment (control groups) and those that receive standard treatment as well as their own bone marrow (experimental groups). Participants will be monitored for complications and for changes in their condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Investigation on Autologous Mesenchymal Stem Cell Transplantation in Diabetic Retinopathy Location: Iran
    Overview: This trial aims to investigate the effect of patient's own bone marrow stem cells in the treatment of retinopathy due to type 1 diabetes. The trial being conducted by the Teheran University of Medical Sciences and expects to enrol 20 patients by end 2013. All participants will have stem cells harvested from their bone marrow and expanded in the laboratory before being intravenously (IV) transfused into the participants. Participants will be monitored for complications and improvements in their condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Tissue Distribution of Labelled Autologous Bone Marrow Derived Stem Cells in Patients with Type 2 DM Location: India
    Overview: This trial aims to investigate the ability of the stem cells to enhance insulin production in patients with type 2 diabetes. The trial is being conducted by the Postgraduate Institute of Medical Research in Chandigarh in Punjab and will compare different methods of delivering the patient's own bone marrow stem cells. The stem cells will be labelled and where the injected stem cells travel in the body will be monitored using positron emission tomography (PET) scanning. All participants will have stem cells harvested from their bone marrow, expanded in the laboratory and labelled a tracer (F18-FDG). Participants will be randomly divided to four groups. The first group will have labelled stem cells injected via the superior pancreaticoduodenal artery. The second group will have the label stem cells injected into the splenic artery. The third group will have the stem cells infused intravenously (IV) and the final group will have a placebo saline intravenous infusion. The distribution of these labelled stem cells will be monitored by PET scanning 30 minutes and 90 minutes following the injection. Participants will be monitored for complications and changes in their condition. The study expects to enrol 28 patients by end 2013.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Safety and Efficacy Study of Autologous Bone Marrow Stem Cell Transplantation for the Treatment of Diabetic Neuropathy Location: China
    Overview: This trial aims to investigate whether stem cells from the patient's own bone marrow can improve neurological function in diabetic neuropathy. The trial is being conducted by Central Hospital of Wuhan; Tongji Medical College, and Huazhong University of Science and Technology and seeks to enrol 100 patients. Participants will be randomly divided into either a group that only receives conventional treatment for diabetes (control group), and another groups that will receive an infusion of stem cells obtained from the patient's own bone marrow. Participants will be monitored for complications and changes in clinical condition. The trial is scheduled to run from October 2010 to December 2013.
    Link to Clinical Registry
    Trial Design: Therapeutic intervention
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Cultured Mesenchymal Stem Cell Transplantation in T2DM Location: India
    Overview: This trial is investigating the efficacy of stem cells derived from the patient's own bone in the treatment of type 2 diabetes. The trial is being conducted at the Postgraduate Institute of Medical Research in Chandigarh and proposes to recruit 30 subjects between December 2012 and June 2015. Mesenchymal stem cells will be harvested from the patient's own bone marrow and expanded in the laboratory. Participants will be randomly assigned to either an experimental group that will receive an injection of the expanded stem cells (via the superior Pancreaticoduodenal artery), or a control group which will a placebo injection of bone marrow plus vitamin B complex in exactly the same manner as the experimental group. All participants will be monitored for complications and assessed for changes in their clinical condition, including changes in insulin requirement as well as glucagon stimulated C peptide levels.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells